Isocitrate Dehydrogenase 1 R132H mutant, Recombinant Human
Isocitrate dehydrogenase [NADP] cytoplasmic, R132H, IDH 1 R132H
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O75874 |
---|---|
Calculated MW | 50.9 kDa |
Gene ID | 3417 |
---|---|
Other Names | Isocitrate dehydrogenase [NADP] cytoplasmic, R132H, IDH 1 R132H |
Gene Source | Human |
Source | E. Coli |
Assay&Purity | SDS-PAGE;≥90% |
Recombinant | Yes |
Application Notes | Reconstitute in deionized water to the final concentration 0.5 mg/ml and incubate the reconstituted protein at 25 °C for 15 minutes. |
Format | Lyophilized |
Storage | -20°C;N/A |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Mutations of the cytosolic IDH 1 are a common feature in primary human brain cancers. Arginine 132 (R132) of IDH is highly conserved among different isoforms of IDH and is most commonly mutated to Histidine. Mutation of IDH1 R132H leads to accumulation of R(-)-2-hydroxyglutarate (2HG), which correlates with an increased risk for malignant brain tumors.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.